** JonesTrading raises PT on drug developer Monopar Therapeutics MNPR.O to $37 from $9
** Brokerage says MNPR signed agreement with AstraZeneca AZN.L unit Alexion for exclusive worldwide licensing of ALXN-1840 for the treatment of Wilson's disease
** Wilson's disease is a rare genetic condition that causes the buildup of copper to toxic levels
** JonesTrading says ALXN-1840 has the potential to give MNPR a steady cash flow to fund other development efforts
** Brokerage reiterates "buy" rating; PT of $37 is ~94.6% upside on stock's last close
** All of three brokerages rate the stock "buy"; their median PT is $23 - LSEG data
** As of last close, stock up ~1,017.6% YTD
(Reporting by Prakhar Srivastava in Bengaluru)
((Prakhar.srivastava2@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。